Surge In Partnerships And Licensing In China Highlights Need For Greater Flexibility
This article was originally published in The Pink Sheet Daily
As cross-border deals rise rapidly and finding new partners becomes harder in China, multinational drug makers must be flexible in their deal strategies. Seasoned executives from AstraZeneca, Bayer, Merck and Chinese startup Ascletis offer insights on what to look for in a dynamic market.
You may also be interested in...
Merck announced March 15 that it plans to invest $90 million over the next seven years in a nonprofit biomedical research center in San Diego dubbed the California Institute for Biomedical Research, or Calibr.
A new commissioner has taken the reins at China's National Medical Products Administration, but the senior CCP official has so far given few clear indications about the changes he might bring.
Within a month of obtaining its global first approval in China, Hua Medicine's dorzagliatin is already available in hospitals. What was behind the successful launch of the first-in-class diabetes agent, what are reimbursement plans and how will local commercialization partner Bayer help? Founder and CEO Li Chen sits down to discuss these and other strategies.